دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Itch – The major symptom of skin disease and yet still enigmatic
J. Ring
doi : 10.1111/jdv.17166
Volume 35, Issue 4 p. 780-780
The emerging role of autoreactive antibodies in inflammatory skin diseases
I. Kortekaas Krohn
doi : 10.1111/jdv.17164
Volume 35, Issue 4 p. 781-782
Self-reactive antibodies have been identified in various chronic inflammatory skin diseases, such as chronic spontaneous urticarial,1 atopic dermatitis,2, 3 systemic lupus erythematosus4 and autoimmune bullous diseases.5 The presence of these autoreactive antibodies against epitopes in the skin is assumed to contribute to the disease pathophysiology. Active participation of autoreactive antibodies in the inflammatory response may explain the chronic and relapsing course of the disease, which is driven by a systemic mechanism rather than a local inflammation. Several isotypes of autoantibodies have been identified, including IgG, IgM, IgA and IgE, referring to different underlying mechanisms of autoreactivity. Despite differences in the pathophysiology in these skin diseases, current unmet medical needs are similar. Little is known about the clinical relevance of the autoantibodies and their contribution to the disease mechanisms. It is still unclear whether the presence of autoantibodies constitutes a distinct disease endotype or whether this is just an epiphenomenon secondary to the ongoing inflammation. In patients with systemic lupus erythematosus, the presence of dsDNA-specific IgE is related to disease activity and has a predictive value for disease development.6 However, this is not clear for all inflammatory skin diseases. These clinical gaps may directly affect diagnosis and can make a difference in therapeutic strategies. Therefore, research in this field is of great importance to improve diagnosis and personalized therapeutic approaches.
Epidemiology of rare diseases is important
L. Bruckner-Tuderman
doi : 10.1111/jdv.17165
Volume 35, Issue 4 p. 783-784
Rare diseases are an emerging public health priority in Europe.1 It has been estimated that there are more than 6000 distinct rare diseases; all organ systems can be affected. More than 70% of rare diseases are genetic and most of them show a chronic course.1 In the EU, rare diseases are defined as conditions that affect less than 50 persons per 100 000 population. The American orphan drug act from the year of 1983 defined rare diseases as disorders that affect less than 200 000 persons in the country, which at that time corresponded to a prevalence of 86 per 100 000 population.1
Pioneers in Dermatology and Venereology: an interview with Professor Olle Lark?
O. Lark?
doi : 10.1111/jdv.17186
Volume 35, Issue 4 p. 785-786
A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force
L. Misery, A. Belloni Fortina, M. El Hachem, P. Chernyshov, L. von Kobyletzki, A. Heratizadeh, D. Marcoux, V. Aoki, M.C. Zaniboni, J.-F. Stalder, L.F. Eichenfield
doi : 10.1111/jdv.16916
Volume 35, Issue 4 p. 787-796
Atopic dermatitis (AD) is a disease that can have a high impact on quality of life, especially due to itch and skin pain. This paper utilizes expertise from members of the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force to review the epidemiology, pathophysiology and exacerbating factors of itch and pain in atopic dermatitis. General principles of treatment are provided, as well as a more detailed evaluation of topical and systemic therapies. Educational and psychological approaches to itch and pain in atopic dermatitis are proposed, along with expert recommendations for the management of itch and pain in atopic dermatitis.
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond
J. Beecker, K.A. Papp, J. Dutz, R.B. Vender, R. Gniadecki, C. Cooper, P. Gisondi, M. Gooderham, C.H. Hong, M.G. Kirchhof, C.W. Lynde, C. Maari, Y. Poulin, L. Puig
doi : 10.1111/jdv.17075
Volume 35, Issue 4 p. 797-806
Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel RNA virus that was declared a global pandemic on 11 March 2020. The efficiency of infection with SARS-CoV-2 is reflected by its rapid global spread. The SARS-CoV-2 pandemic has implications for patients with inflammatory skin diseases on systemic immunotherapy who may be at increased risk of infection or more severe infection. This position paper is a focused examination of current evidence considering the mechanisms of action of immunotherapeutic drugs in relation to immune response to SARS-CoV-2. We aim to provide practical guidance for dermatologists managing patients with inflammatory skin conditions on systemic therapies during the current pandemic and beyond. Considering the limited and rapidly evolving evidence, mechanisms of action of therapies, and current knowledge of SARS-CoV-2 infection, we propose that systemic immunotherapy can be continued, with special considerations for at risk patients or those presenting with symptoms.
Genodermatoses with itch as a prominent feature
K. Fourzali, G. Yosipovitch
doi : 10.1111/jdv.16963
Volume 35, Issue 4 p. 807-814
A number of inherited conditions cause chronic itch as a part of the recognized phenotype. Advances in the understanding of the genetic factors that cause these diseases elucidate the molecular underpinning of itch as a symptom. Our knowledge of the causes of chronic itch has also advanced, providing an opportunity to integrate the genetic pathophysiology with the molecular landscape of chronic itch mediators. This article reviews select genodermatoses that have itch as a predominant feature with a focus on the pathophysiology of the disease, how it may lead to itch and potential therapeutic targets.
Actinic cheilitis: a systematic review of treatment options
M.H. Trager, K. Farmer, C. Ulrich, N. Basset-Seguin, F. Herms, L.J. Geskin, J.-D. Bouaziz, C. Lebbé, A. de Masson, M. Bagot, G. Dobos
doi : 10.1111/jdv.16995
Volume 35, Issue 4 p. 815-823
Actinic cheilitis is a premalignant condition that can progress to squamous cell carcinoma with a higher propensity for metastasis than cutaneous squamous cell carcinoma. Optimal treatment for actinic cheilitis has not been established, and evidence-based estimates of clinical cure in the dermatology literature are limited. Here, we review and synthesize outcome data published for patients with actinic cheilitis after treatment with various modalities. A systematic review was conducted in MEDLINE, Embase and the Cochrane library for English, French and German-language studies and references of included articles from inception to 20 January 2020. Studies were included if they reported on at least six patients with biopsy-proven actinic cheilitis. After quality appraisal, results of studies with the strongest methodology criteria were synthesized. 18 studies of 411 patients (published 1985 to 2016) were included. The majority of the studies were case series. Carbon dioxide laser ablation and vermilionectomy were associated with the most favourable outcomes with fewest recurrences. Chemical peel and photodynamic therapy were associated with higher recurrence. Adverse effects generally resolved in the weeks following treatment and cosmetic outcomes were favourable overall. In conclusion, there is a lack of high-quality comparative studies evaluating different treatment options for actinic cheilitis. The included publications used various outcome measures; however, the majority reported on the recently defined core outcome sets. These results suggest that both carbon dioxide laser ablation and vermilionectomy are effective treatments for actinic cheilitis. Prospective head-to-head studies are needed to compare these treatment modalities and to assess patient preferences.
Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis – time for a paradigm change
M. Nogueira, R.B. Warren, T. Torres
doi : 10.1111/jdv.16866
Volume 35, Issue 4 p. 824-834
Tuberculosis is an infectious disease with a major global impact, ranked in the top 10 mortality causes worldwide. In an immunocompetent individual, the host defence mechanisms control Mycobacterium tuberculosis infection and induce the latent form of the disease. However, in the presence of diseases or therapies, which exert an immunosuppressive effect, latent tuberculosis can be re-activated. Psoriasis is an immune-mediated, inflammatory disease, and its treatment has rapidly evolved over the last few years. It has long been recognized that the tumour necrosis factor (TNF)-? inhibitors are associated with increased risk of reactivation of latent tuberculosis infection. Thus, international guidelines have been suggesting tuberculosis screening before starting the treatment with all biological agents since then. In addition, the institution of chemoprophylaxis in the presence of latent tuberculosis and the annual screening for tuberculosis thereafter have also been indicated. However, anti-tuberculosis treatments can have significant side-effects and there are currently several contraindications to their use. The risk benefit of starting anti-tuberculous treatment should be carefully weighed up. The emergence of new biological drugs for the treatment of psoriasis, such as interleukin (IL)-17 and IL-23 inhibitors, has reignited the subject of tuberculosis reactivation as it is possible that IL-17 and 23 blockade do not carry the same risk of TB reactivation as TNF-? inhibitors. Although preclinical studies have shown that cytokines IL-17 and IL-23 have a possible role against infection with M. tuberculosis, data from clinical trials and post-marketing surveillance with drugs that inhibit these cytokines appear to suggest that they are not crucial to this response. In this article, we review the available data on tuberculosis reactivation after the treatment of psoriasis with IL-17 and IL-23 inhibitors, and its possible impact on the way we currently manage latent tuberculosis infection before or after starting treatment with these new drugs.
Social and psychosocial effects on atopic eczema symptom severity – a scoping review of observational studies published from 1989 to 2019
K. Zeiser, G. Hammel, I. Kirchberger, C. Traidl-Hoffmann
doi : 10.1111/jdv.16950
Volume 35, Issue 4 p. 835-843
Social and psychosocial factors are thought to have an effect on the course of atopic eczema. The aim of this scoping review was to search for and summarize observational studies that investigated the effects of (psycho-)social factors on symptoms in atopic eczema and to identify research gaps. We searched PubMed and PsycINFO for literature published between 1 January 1989 and 31 December 2019 using a systematic search strategy. We included observational studies that analysed the effect of (psycho-)social factors on symptom severity in atopic eczema patients. Reviews and non-observational studies, articles with research on animals, and articles with languages other than English or German were excluded. We identified 17 observational studies that met the inclusion criteria. Several studies found significant results for an exacerbating effect of stress on atopic eczema severity. Although coping and social support does not seem to moderate the effect of stress, coping strategies might mediate the impact that stress has on symptoms. Depression is associated with atopic eczema severity. The effect of depression as a consequence of atopic eczema severity is stronger than the effect as an exacerbating factor. Illness identity, anger, frustration and psychosomatic states have been found to affect atopic eczema symptoms. For attachment security, anxiety and social status, contradictory results were found. Statistically non-significant results were reported for personality, being in a partnership, satisfaction with the partnership, childhood experiences and body consciousness. Only the association between psychosocial stress and atopic eczema symptom severity seems robust. To date, other (psycho-)social factors, especially protective and health-promoting factors, were analysed only in a few studies, mostly with low sample sizes and cross-sectional design. Biopsychosocial interactions between stress, protective factors and the course of atopic eczema as well as the psycho-neuroimmunological mechanisms underlying those interactions are considered fields for future research contributions.
A systematic review of worldwide data on tinea capitis: analysis of the last 20 years
C. Rodr?guez-Cerdeira, E. Mart?nez-Herrera, J.C. Szepietowski, R. Pinto-Almaz?n, M.G. Fr?as-De-Le?n, V.M. Espinosa-Hern?ndez, E. Ch?vez-Gutiérrez, E. Garc?a-Salazar, D.C. Vega-S?nchez, R. Arenas, R. Hay, D.M. Saunte
doi : 10.1111/jdv.16951
Volume 35, Issue 4 p. 844-883
Dermatophyte infections are the most common fungal infections in humans; among them, tinea capitis (TC) – the most contagious fungal infection – is caused by anthropophilic, zoophilic and geophilic dermatophytes. The purpose of this systematic review was to determine the different aetiological variants involved in TC and the overall epidemiology of the causes of this infection in the last two decades. We searched the MEDLINE (PubMed) and Embase databases for articles published from July 2000 to August 2019 using the following search terms: ‘Tinea capitis’, ‘Africa’, ‘America’, ‘Asia’, ‘Europe’, ‘Oceania’, and the names of the countries on each continent. The flow of information through the different phases in this systematic review was depicted using a PRISMA flow diagram, which mapped the number of records identified, included and excluded, and the reasons for exclusion. Our findings indicate that the frequency of different aetiologic agents of TC in the reported studies varied globally, from 0.4–87.7% in Africa, 0.2–74.0% in North America, 0.0–91.2% in Eastern Asia, 0.0–69.0% in Eastern Europe and 2.9–86.4% in Oceania. Microsporum canis is the most frequent reported zoophilic agent worldwide, while Trichophyton violaceum and Trichophyton tonsurans are the predominant anthropophilic agents. Over time, the frequency of these latter fungal infections has increased globally, and these fungi have become the major species globally. Anthropophilic transmission – the most prevalent type of transmission – could be explained by two factors: (i) the socioeconomic status of affected countries and population groups with associated risk factors and (ii) movement of populations importing new causes of infection to areas where they had not been encountered previously. We observed that intercontinental migration and travel; globalization; environmental, climatic and ecological changes; and accelerated evolution of health technologies may influence the observed epidemiological changes and, consequently, contributed to the variations in the global status of TC.
Cutaneous malignant melanoma mortality in Spain from 1979 to 2018. Trends and new perspectives in the immunotherapy era
A.J. Dur?n-Romero, M. Send?n-Martin, J. Conejo-Mir, J.J. Pereyra-Rodriguez
doi : 10.1111/jdv.16983
Volume 35, Issue 4 p. 884-891
Recent studies suggest that cutaneous melanoma mortality rates in Spain are stabilizing and even decreasing in younger cohorts.
Association between the dermoscopic morphology of peripheral globules and melanocytic lesion diagnosis
O. Reiter, E. Chousakos, N. Kurtansky, J.K. Nanda, S.W. Dusza, M.A. Marchetti, N. Jaimes, A. Moraes, A.A. Marghoob
doi : 10.1111/jdv.17035
Volume 35, Issue 4 p. 892-899
The presence of peripheral globules is associated with enlarging melanocytic lesions; however, there are numerous patterns of peripheral globules distribution and it remains unknown whether specific patterns can help differentiate enlarging naevi from melanoma.
Dermatoscopy of combined blue nevi: a multicentre study of the International Dermoscopy Society
J. Stojkovic-Filipovic, D. Tiodorovic, A. Lallas, B.N. Akay, C. Longo, C. Rosendahl, D. Dobrosavljevic, G. Nazzaro, G. Argenziano, I. Zalaudek, I. Tromme, P. Tschandl, S. Puig, S. Lanssens, H. Kittler
doi : 10.1111/jdv.17059
Volume 35, Issue 4 p. 900-905
Combined blue nevi (CBN) may mimic melanoma and are relatively often biopsied for diagnostic reasons.
Developing a predictive model for distinguishing invasive nail unit melanoma from nail unit melanoma in situ
J. Ohn, K. Hur, Y. Cho, J. Park, J.Y. Kim, S.-J. Lee, H. Park, J.-H. Mun
doi : 10.1111/jdv.17036
Volume 35, Issue 4 p. 906-911
Clinical information that distinguishes invasive nail unit melanoma from nail unit melanoma in situ before surgery would aid physicians in the decision-making process and estimating prognosis. However, limited information is available on the detailed demographic and dermoscopic features of invasive nail unit melanoma and nail unit melanoma in situ for differential diagnosis.
Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study
M.-A. Richard, C. Paul, G. De Pouvourville, D. Jullien, E. Mahe, H. Bachelez, J. Seneschal, L. Misery, R. Aubert, Z. Reguiai, J. Shourick, C. Taieb, P. Joly, K. Ezzedine
doi : 10.1111/jdv.17000
Volume 35, Issue 4 p. 912-918
In 2018 in France, overall mean health-related out-of-pocket (OOP) expenditures were 214.00€/year/patient.
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
R.B. Warren, J.M. Carrascosa, E. Fumero, A. Schoenenberger, M.G. Lebwohl, J.C. Szepietowski, K. Reich
doi : 10.1111/jdv.16964
Volume 35, Issue 4 p. 919-927
As treatment interruptions occur during psoriasis management in clinical practice, it is important to know the duration of clinical response after treatment withdrawal.
Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials
P. Hampton, A. Halliday, M. Aassi, S. Subramanian, M. Jain, C.E.M. Griffiths
doi : 10.1111/jdv.16982
Volume 35, Issue 4 p. 928-937
The efficacy of biologic therapies is greater among biologic-naïve vs. biologic-experienced psoriasis patients. However, little is known as to whether prior use of other systemic therapies impacts secukinumab efficacy in patients with moderate-to-severe psoriasis.
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial
C. Bodemer, A. Kaszuba, K. Kingo, A. Tsianakas, A. Morita, E. Rivas, P. Papanastasiou, D. Keefe, M. Patekar, P. Charef, L. Zhang, S. Cafoncelli, C. Papavassilis
doi : 10.1111/jdv.17002
Volume 35, Issue 4 p. 938-947
Secukinumab has demonstrated sustained long-term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults.
Disease severity and trigger factors in Danish children with atopic dermatitis: a nationwide study
T. Gerner, J.H. Haugaard, C. Vestergaard, M. Deleuran, G.B. Jemec, C.G. Mortz, T. Agner, A. Egeberg, L. Skov, J.P. Thyssen
doi : 10.1111/jdv.17007
Volume 35, Issue 4 p. 948-957
Atopic dermatitis (AD) is a prevalent chronically relapsing inflammatory skin disease of childhood. However, little is known about self-reported trigger factors, impact on daily life and factors associated with AD severity.
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study
C. Patruno, M. Napolitano, G. Argenziano, K. Peris, M. Ortoncelli, G. Girolomoni, A. Offidani, S.M. Ferrucci, G.F. Amoruso, M. Rossi, L. Stingeni, G. Malara, T. Grieco, C. Foti, M. Gattoni, C. Loi, M. Iannone, M. Talamonti, G. Stinco, F. Rongioletti, P.D. Pigatto, A. Cristaudo, E. Nettis, M. Corazza, F. Guarneri, P. Amerio, M. Esposito, A. Belloni Fortina, C. Potenza, G. Fabbrocini, DADE - Dupilumab for Atopic Dermatitis of the Elderly study group
doi : 10.1111/jdv.17094
Volume 35, Issue 4 p. 958-964
Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known.
Experimental evaluation of nickel and cobalt release from tools and self-reported prevalence of nickel and cobalt allergy in the German hairdressing trade
C. Symanzik, C. Skudlik, S.M. John
doi : 10.1111/jdv.17058
Volume 35, Issue 4 p. 965-972
Nickel release from some metal tools in the hairdressing trade has been sporadically evidenced, whereas data about cobalt release from metal tools in the hairdressing trade are lacking.
IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients
A. Lamberts, N. Kotnik, G.F.H. Diercks, J.M. Meijer, G. Di Zenzo, H.H. Pas, M.F. Jonkman, B.F. Gibbs, U. Raap, B. Horv?th
doi : 10.1111/jdv.16996
Volume 35, Issue 4 p. 973-980
Non-bullous pemphigoid (NBP) is a pemphigoid variant which frequently resembles other pruritic skin diseases. In contrast with bullous pemphigoid (BP), blisters are absent. In BP, previous studies showed that IgE autoantibodies may be involved in its pathogenesis. IgE-activated mast cells, basophils and eosinophils may participate in BP by inducing pruritus and possibly blister formation, although the differential role of IgE in NBP compared with BP has not yet been described.
Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies
S. St?nder, E. Schmidt, D. Zillikens, D. Thaçi, R.J. Ludwig, K. Kridin
doi : 10.1111/jdv.17013
Volume 35, Issue 4 p. 981-987
Although the association of bullous pemphigoid (BP) and psoriasis is well-established, the clinical and immunological features of patients with coexisting BP and psoriasis are yet to be investigated.
Reactive granulomatous dermatitis as a histological pattern including manifestations of interstitial granulomatous dermatitis and palisaded neutrophilic and granulomatous dermatitis: a study of 52 patients
N. Rodr?guez-Garijo, I. Bielsa, J.M. Mascar? Jr, A. Quer, M.A. Idoate, J.J. Paricio, P. Iranzo, A. Espa?a
doi : 10.1111/jdv.17010
Volume 35, Issue 4 p. 988-994
Confusion exists regarding interstitial granulomatous dermatitis (IGD) and palisaded neutrophilic and granulomatous dermatitis (PNGD).
Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?
R. Baardman, V.K. Yenamandra, J.C. Duipmans, A.M.G. Pasmooij, M.F. Jonkman, P.C. van den Akker, M.C. Bolling
doi : 10.1111/jdv.17012
Volume 35, Issue 4 p. 995-1006
Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic disorders characterized by fragility of the skin and mucosae, resulting in blisters and erosions. Several epidemiological studies in other populations have been carried out, reporting varying and sometimes inconclusive figures, highlighting the need for standardized epidemiological analyses in well-characterized cohorts.
Immunofluorescence mapping, electron microscopy and genetics in the diagnosis and sub-classification of inherited epidermolysis bullosa: a single-centre retrospective comparative study of 87 cases with long-term follow-up
S. Rossi, D. Castiglia, E. Pisaneschi, A. Diociaiuti, A. Stracuzzi, C. Cesario, R. Mariani, G. Floriddia, G. Zambruno, R. Boldrini, D. Abeni, A. Novelli, R. Alaggio, M. El Hachem
doi : 10.1111/jdv.17060
Volume 35, Issue 4 p. 1007-1016
Epidermolysis bullosa (EB) comprises a heterogeneous group of skin fragility disorders, classified in four major types based on skin cleavage level, i.e. EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), Kindler EB, and in more than 30 subtypes defined by the combination of laboratory and clinical data, including disease course.
Epidemiological and clinical aspects of Trichophyton mentagrophytes/Trichophyton interdigitale infections in the Zurich area: a retrospective study using genotyping
M. Klinger, M. Theiler, P.P. Bosshard
doi : 10.1111/jdv.17106
Volume 35, Issue 4 p. 1017-1025
Trichophyton mentagrophytes (formerly Arthroderma vanbreuseghemii) and its clonal offshoot Trichophyton interdigitale, which are leading causes of dermatophytoses, have recently been recognized as two separate species. Over the last 20 years, several internal transcribed spacer (ITS) genotypes of Trichophyton mentagrophytes and Trichophyton interdigitale have been identified, some of which have specific characteristics and lead to typical clinical manifestations.
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia
J. McCoy, F.A. Cadegiani, C.G. Wambier, S. Herrera, S. Va?o-Galv?n, N.A. Mesinkovska, P.M. Ramos, J. Shapiro, R. Sinclair, A. Tosti, A. Goren
doi : 10.1111/jdv.17021
Volume 35, Issue 4 p. e243-e246
Pityriasis rosea as a leading manifestation of COVID-19 infection
R. Merhy, A.S. Sarkis, F. Stephan
doi : 10.1111/jdv.17052
Volume 35, Issue 4 p. e246-e247
Palmoplantar erythrodysesthesia: a diagnostic sign of COVID-19
A. Nuno-Gonzalez, K. Magaletsky, M. Feito Rodr?guez, A. Mayor Ibarguren, M.J. Beato, E. Ruiz Bravo, P. Herranz Pinto
doi : 10.1111/jdv.17074
Volume 35, Issue 4 p. e247-e249
Understanding views of patients on biologics for psoriasis amid the COVID-19 pandemic
K. Pandher, C.L. Porter, H.S. Patel, W.W. Huang, S.R. Feldman
doi : 10.1111/jdv.17091
Volume 35, Issue 4 p. e249-e251
Drug repurposing through drug–gene interaction profiles for hidradenitis suppurativa/acne inversa treatment
C.C. Zouboulis, A. Nogueira da Costa
doi : 10.1111/jdv.16976
Volume 35, Issue 4 p. e251-e254
BRIT-1 expression and its relationship with PARP-1 and CAF-1/p60 in cutaneous melanoma
D. Russo, A. Travaglino, S. Varricchio, F. Merolla, G. Ilardi, A. Raffone, M. Scalvenzi, C. Costa, G. Fabbrocini, S. Staibano, M. Mascolo
doi : 10.1111/jdv.16977
Volume 35, Issue 4 p. e254-e257
Cutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis due to MPL gene mutation
Y. Murase, T. Takeichi, K. Tanahashi, Y. Marumo, Y. Suzuki, S. Nakamura, M. Akiyama
doi : 10.1111/jdv.16990
Volume 35, Issue 4 p. e257-e259
Langerhans cell histiocytosis mimicking prurigo nodularis
S. Traidl, Y. Angela, B. Wedi, A. Kapp, T. Werfel, V. Schacht
doi : 10.1111/jdv.16991
Volume 35, Issue 4 p. e259-e261
Cutaneous incidentaloma revealed by [18F]-FDG-PET/CT
Y. Maya, Y. Fujita, T. Mizukami, T. Takei, S. Shimizu
doi : 10.1111/jdv.16992
Volume 35, Issue 4 p. e261-e263
Ex vivo confocal laser scanning microscopy with digital staining is able to map characteristic histopathological features and tissue reaction patterns of inflammatory skin diseases
J. Mentzel, M.-M. Stecher, U. Paasch, J.C. Simon, S. Grunewald
doi : 10.1111/jdv.17006
Volume 35, Issue 4 p. e263-e265
A proposed new category of cutaneous segmental mosaicism: Isolated segmental biallelic monoclonal mosaicism
A. Torrelo, R. Happle
doi : 10.1111/jdv.17008
Volume 35, Issue 4 p. e265-e267
Darier disease restricted to the buttocks
X.L. Zhang, W. Zhang, Y. Liu, W. Hou
doi : 10.1111/jdv.17019
Volume 35, Issue 4 p. e268-e269
Pregnancy-triggered atypical extrapalmoplantar erythematous hyperkeratotic lesions in palmoplantar keratoderma with mitochondrial mutations
O. Ansai, R. Hayashi, A. Nakamura, A. Arimatsu-Sato, A. Hasegawa, A. Yuki, A. Fujimoto, N. Hama, S. Shinkuma, Y. Shimomura, R. Abe
doi : 10.1111/jdv.17020
Volume 35, Issue 4 p. e269-e272
Metascoring Hidradenitis suppurativa
M. Daoud, H. Njimi, F. Benhadou, M. Suppa, M. Daxhelet, J. Karama, J. White, G.B.E. Jemec, V. del Marmol
doi : 10.1111/jdv.17022
Volume 35, Issue 4 p. e272-e274
European registry for hidradenitis suppurativa: state of play
M. Daxhelet, M. Daoud, M. Suppa, F. Benhadou, H. Njimi, T. Tzellos, C.C. Zouboulis, G.B. Jemec, V. del Marmol
doi : 10.1111/jdv.17023
Volume 35, Issue 4 p. e274-e276
No association between atopic dermatitis and acne vulgaris in the general population
A.-S. Halling, G.B.E. Jemec, A. Linneberg, J.P. Thyssen
doi : 10.1111/jdv.17040
Volume 35, Issue 4 p. e276-e278
Has the migratory wave altered the fungal landscape in Greece? A 5-year epidemiological study from a mycological reference centre in Northern Greece
I. Papadimitriou, K. Bakirtzi, N. Sideris, E. Paschou, F. Vrani, E. Vakirlis, A. Lallas, D. Ioannides, E. Sotiriou
doi : 10.1111/jdv.17042
Volume 35, Issue 4 p. e278-e280
Disseminated bullous impetigo in atopic dermatitis (‘eczema staphylococcatum’)
L. Koch, U. Cerpes, B. Binder, L. Cerroni
doi : 10.1111/jdv.17043
Volume 35, Issue 4 p. e280-e282
A case of non-bullous pemphigoid induced by IgG4 autoantibodies targeting BP230
N. Yoshimoto, S. Takashima, T. Kawamura, E. Inamura, T. Sugai, I. Ujiie, K. Izumi, K. Natsuga, W. Nishie, H. Shimizu, H. Ujiie
doi : 10.1111/jdv.17044
Volume 35, Issue 4 p. e282-e285
Our experience with prurigo nodularis treated with dupilumab
G. Tilotta, G. Pistone, P. Caruso, R. Gurreri, E. Castelli, S. Curiale, V. Caputo, M.R. Bongiorno
doi : 10.1111/jdv.17046
Volume 35, Issue 4 p. e285-e287
Efficacy of 308-nm excimer laser treatment for refractory vitiligo: a case series of treatment based on the minimal blistering dose
R. Noborio, Y. Nomura, M. Nakamura, E. Nishida, T. Kiyohara, H. Tanizaki, A. Morita
doi : 10.1111/jdv.17047
Volume 35, Issue 4 p. e287-e289
Association between atopic dermatitis and nasal polyposis: what is the evidence?
A.-S. Halling, M. van Hauen, V.H. Eggers-Lura, M.H. Knudgaard, N. Loft, J.P. Thyssen
doi : 10.1111/jdv.17048
Volume 35, Issue 4 p. e290-e293
Genomic mutational profiling of circulating tumour DNA in metastatic angiosarcoma
K. Tanaka, T.M. Myangat, S. Sawamura, S. Otsuka-Maeda, R. Sakamoto, S. Kanazawa-Yamada, H. Kanemaru, K. Makino, J. Aoi, I. Kajihara, H. Ihn
doi : 10.1111/jdv.17049
Volume 35, Issue 4 p. e293-e295
De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort
L. Jaulent, D. Staumont-Sallé, M. Tauber, C. Paul, H. Aubert, A. Marchetti, B. Sassolas, A. Valois, J.-F. Nicolas, A. Nosbaum, for GREAT Research Group
doi : 10.1111/jdv.17050
Volume 35, Issue 4 p. e296-e297
Clinicodermoscopic observation of secondary recurrent syphilis with annular scaly lesions on the penis
Y.-J. Wang, Q. Wang, X.-X. Pi, Y.-M. Fan
doi : 10.1111/jdv.17054
Volume 35, Issue 4 p. e298-e299
Treatment of nail psoriasis with brodalumab: an open-label unblinded study
S. Gregoriou, A. Tsiogka, A. Tsimpidakis, E. Nicolaidou, G. Kontochristopoulos, D. Rigopoulos
doi : 10.1111/jdv.17055
Volume 35, Issue 4 p. e299-e301
Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients
D. Jullien, C. Paul, J. Shourick, J. Sénéschal, G. de Pouvourville, L. Misery, E. Mahé, H. Bachelez, R. Aubert, P. Joly, S. Héas, Z. Reguiai, K. Ezzedine, C. Taieb, M.A. Richard
doi : 10.1111/jdv.17056
Volume 35, Issue 4 p. e301-e303
Comparison of the efficacy between topical timolol and pulsed dye laser in the treatment of ulcerated infantile haemangiomas: a randomized controlled study
Q.Y. Chen, L. Chang, Y.J. Qiu, H.R. Ying, S.J. Chang, Y. Zhang, Z.A. Chen, G. Ma, X.X. Lin
doi : 10.1111/jdv.17057
Volume 35, Issue 4 p. e303-e305
Use of mind-body practices by patients with psoriasis: results from a study on 2562 patients
L. Misery, J. Shourick, J. Sénéschal, C. Paul, G. de Pouvourville, D. Jullien, E. Mahé, H. Bachelez, R. Aubert, P. Joly, S. Héas, Z. Reguiai, K. Ezzedine, C. Taieb, M.A. Richard
doi : 10.1111/jdv.17061
Volume 35, Issue 4 p. e305-e307
